Short answer · Medically reviewed summary · Last updated: 2026-05-08
CLOVES syndrome treatment is highly personalized, focusing on managing complex overgrowth, vascular malformations, and potential complications through a combination of targeted systemic therapy and surgical intervention. Management is best coordinated by a multidisciplinary team to address the specific, evolving clinical needs of each individual patient. What are the primary medical treatments for CLOVES syndrome? The standard of care for CLOVES syndrome has shifted significantly with the use of PI3K inhibitors.
CLOVES syndrome treatment is highly personalized, focusing on managing complex overgrowth, vascular malformations, and potential complications through a combination of targeted systemic therapy and surgical intervention. Management is best coordinated by a multidisciplinary team to address the specific, evolving clinical needs of each individual patient.
The standard of care for CLOVES syndrome has shifted significantly with the use of PI3K inhibitors. Sirolimus (Rapamune) has historically been used to manage vascular malformations and overgrowth, but Alpelisib (Piqray) is increasingly utilized as a targeted therapy to inhibit the PI3K pathway directly. Because CLOVES syndrome is caused by somatic mutations in the PIK3CA gene, these medications aim to reduce the size of vascular lesions and manage the progressive overgrowth associated with the condition.
Surgical management for CLOVES syndrome is complex and typically reserved for functional impairment or severe pain. Multidisciplinary care often includes:
Due to the multisystem nature of CLOVES syndrome, care must be managed by a team of experts. Recommended specialists typically include a pediatric geneticist, a vascular anomalies specialist, an orthopedic surgeon, a dermatologist, and a physical therapist. At DiseaseMaps.org, our community of 7 members highlights the value of sharing experiences with these multidisciplinary teams to navigate the complexities of CLOVES syndrome.
Clinical research into CLOVES syndrome is rapidly evolving. Current clinical trials are focusing on the long-term safety and efficacy of PI3K inhibitors in pediatric populations. Treatment effectiveness varies greatly between patients depending on the specific location and severity of the overgrowth, requiring frequent reassessment by your clinical team.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with your personal healthcare team.